{"id":4277,"date":"2026-10-12T08:32:31","date_gmt":"2026-10-12T08:32:31","guid":{"rendered":"https:\/\/nhdbio.com\/?p=4277"},"modified":"2026-10-12T08:32:31","modified_gmt":"2026-10-12T08:32:31","slug":"cagrisema-grasa-organica-y-marcadores-oseos-explicados","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/cagrisema-organ-fat-bone-markers-explained\/","title":{"rendered":"CagriSema: \u00bfqu\u00e9 cambi\u00f3 en la grasa de los \u00f3rganos y el recambio \u00f3seo?"},"content":{"rendered":"
\n
\"Thematic
Editorial illustration, not an experimental photograph.<\/figcaption><\/figure>\n

The scale shows more than ten kilograms lost, but it does not tell us which part was lost. The CagriSema data announced on September 30 looked separately at organ fat and bone turnover markers. These two parts come from different studies and need to be read separately.<\/p>\n

\n

Why does CagriSema have two names?<\/h2>\n

It is a fixed combination of cagrilintide and semaglutide: the former acts on amylin-related receptors, and the latter acts on GLP-1 receptors. The researchers hope to influence appetite and metabolism together through different signals.<\/p>\n

The results of a combination drug belong to the combination formulation. Not all changes can be attributed to cagrilintide alone, and it cannot be assumed that mixing two research materials in any ratio can replicate the clinical results.<\/p>\n<\/section>\n

\n

The organ fat part comes from REIMAGINE 1<\/h2>\n

The announcement introduced an MRI substudy in patients with early type 2 diabetes. The study observed reductions in abdominal fat and fat related to the liver and pancreas, and reported that the combination treatment led to 14.3% body weight loss at week 40.[1]<\/a><\/p>\n

These examinations focus on where fat is stored. Abdominal fat and fat within organs each have their own measurement methods, and a smaller waist circumference does not mean that fat in the pancreas has decreased by the same proportion.<\/p>\n<\/section>\n

\n

The bone part comes from another trial<\/h2>\n

A post hoc analysis of REIMAGINE 2 looked at bone metabolism markers, which are indicators reflecting the formation and breakdown activity of bone tissue. The announcement reported that along with 14.2% body weight loss at week 68, the related markers provided a preliminary reassuring signal.[1]<\/a><\/p>\n

14.3% corresponds to week 40 of REIMAGINE 1, and 14.2% corresponds to week 68 of REIMAGINE 2. They look close, but they are not two consecutive results from the same group of people.<\/p>\n